DANBURY, Conn.--(BUSINESS WIRE)--Biodel Inc. (Nasdaq: BIOD) announced today that it will report results of its two pivotal Phase III clinical trials of VIAject™ in patients with Type 1 and Type 2 diabetes next week at the 44th Annual Meeting of the European Association for the Study of Diabetes in Rome. Two posters summarizing these results, #677 by Flacke et al. entitled “Insulin VIAject™ and Regular Human Insulin in Patients with Type 1 Diabetes: Efficacy and Safety in an Open-Label Multicenter Clinical Trial”, and #678 by Steiner et al. entitled “Insulin VIAject™ and Regular Human Insulin in Patients with Type 2 Diabetes: Efficacy and Safety in an Open-Label Multicenter Clinical Trial”, will be presented at the conference during Poster Event C, PS 051 Hypoglycaemia which begins on Monday, September 8, 2008. The posters will be available for view at the EASD poster session hall and on the company’s website at www.biodel.com beginning at 3:00 am Eastern Daylight Time (EDT)/9:00 am Central European Summer Time (CEST) on Monday, September 8, 2008. The authors will be present to discuss their work at their respective poster on Tuesday, September 9, 2008 from 12:30 pm to 1:30 pm CEST. Biodel will host a webcast and conference call on September 9, 2008 at 8:00 am EDT/2:00 pm CEST to present and discuss the data and answer questions about the findings.
